Investigational drug · Phase 2
BMB-101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "BMB-101"
First trial start
2024
Dec 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMB-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Absence Epilepsy
- Jeavons Syndrome
- Dravet Syndrome
- Lennox Gastaut Syndrome
- Prader-Willi Syndrome
Approved drugs for the same conditions: Epilepsy and seizures · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BMB-101" as an intervention, largest first.
Bright Minds Biosciences Pty LtdIndustry
NCT05397041 · 81 participants · Start Jun 6, 2022 · Primary completion May 4, 2023
Drug: BMB-101; Placebo · For: Healthy
Sites: Adelaide, Australia
- BMB-101 in Absence Epilepsy and DEERecruiting
Bright Minds Biosciences Pty LtdIndustry
NCT06401538 · 20 participants (planned) · Start Dec 5, 2024 · Primary completion Sep 15, 2025
Drug: BMB-101 · For: Absence Epilepsy; Jeavons Syndrome; Dravet Syndrome and 1 more
Sites: Randwick, Australia; Herston, Australia; Fitzroy, Australia · 5 sites in all
- A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.Not yet recruiting
Bright Minds Biosciences Pty LtdIndustry
NCT07266324 · 16 participants (planned) · Start Jan 2026 · Primary completion Nov 2026
Drug: BMB-101; Placebo · For: Prader-Willi Syndrome
Sites: Sydney, Australia; Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Serotonergic Modulation in Absence Epilepsy: The Role of Thalamo-cortical Networks and 5-hydroxytryptamine Receptors.
Aktemur BH, Saltk ÖD · Acta Neurol Taiwan 2026
- Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.
Bialer M, Johannessen Landmark C, Koepp MJ, et al. · Epilepsia 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.